U.S.-Based Research Chemical Supplier Highlights New Findings on Investigational Triple-Hormone Compound Following Phase 3 Clinical Trial Results
United States, 31st Oct 2026 – New clinical trial findings involving retatrutide are drawing attention across the pharmaceutical and metabolic research sectors after the investigational compound demonstrated significantly greater average weight reduction than semaglutide (Ozempic 2 mg) in a Phase 3 study involving adults with Type 2 diabetes.
Platinum BioLabs, a U.S.-based research chemical supplier specializing in peptides and chemical compounds for laboratory, analytical, and research applications, recognizes the findings as an important development in ongoing research into next-generation peptide compounds and metabolic pathways.
The results, announced by Eli Lilly on October 28, 2026, provide further insight into retatrutide's potential and the growing scientific interest in compounds that interact with multiple hormone receptors.
The TRANSCEND-T2D-2 clinical trial evaluated retatrutide against semaglutide 2 mg over an 80-week treatment period in adults with Type 2 diabetes.
According to the reported findings, participants receiving the 9 mg retatrutide dose experienced an average body-weight reduction of 19.5%, while those receiving the 12 mg dose experienced an average reduction of 20.9%.
By comparison, participants receiving semaglutide 2 mg experienced an average weight reduction of 9.4%.
The results represent more than twice the average weight reduction observed in the semaglutide comparison group at the higher retatrutide dose.
The study also evaluated glycemic control, with retatrutide demonstrating an average A1C reduction of 2.2 percentage points compared with 1.8 percentage points for semaglutide.
These findings are specific to the trial population and treatment conditions. They should not be interpreted as establishing equivalent outcomes across other populations or comparisons with every GLP-1 medication.
Retatrutide is an investigational peptide designed to activate three hormone receptors: GLP-1, GIP, and glucagon. These biological pathways are involved in appetite regulation, glucose metabolism, and energy balance.
Unlike semaglutide, which primarily targets the GLP-1 receptor, retatrutide's triple-receptor mechanism represents a different approach currently being investigated in clinical research.
The compound's clinical development has attracted considerable attention from researchers studying metabolic health, obesity, and emerging peptide-based approaches.
As interest in peptide research continues to expand, Platinum BioLabs emphasizes the importance of reliable research materials, transparent documentation, and consistent quality-control procedures.
The company supplies peptides and chemical compounds for laboratory, analytical, and research applications. Its quality-focused approach includes applicable batch-specific analytical testing, purity verification, lot traceability, controlled packaging procedures, and Certificates of Analysis where available.
Platinum BioLabs operates from the United States, with domestic fulfillment and established supply and manufacturing partners supporting its operations. Where supported by applicable manufacturing documentation, products may undergo processing and lyophilization within the United States.
The company also supports individual research requirements and larger-volume laboratory procurement, with documentation and customer assistance available for applicable products and batches.
Despite the encouraging clinical findings, retatrutide remains investigational and has not received FDA approval. Its safety and effectiveness continue to be evaluated through clinical development.
Platinum BioLabs emphasizes that research chemicals are not approved medicines and are not intended for human consumption, self-administration, or therapeutic use. Researchers should rely on authorized clinical information and applicable regulatory guidance when evaluating investigational compounds.
As scientific understanding of multi-receptor peptide compounds develops, continued clinical investigation and transparent analytical standards remain important to advancing metabolic research.
For more information about Platinum BioLabs and its research chemical supply operations, visit https://platinumbiolabs.com/.
Platinum BioLabs is a U.S.-based research chemical supplier providing peptides and chemical compounds for laboratory and analytical research. The company emphasizes quality-focused sourcing, batch-specific testing, transparent documentation, and dependable U.S.-based fulfillment. Its commitment to research quality includes applicable Certificates of Analysis, product traceability, and responsive customer support.
For more information, visit https://platinumbiolabs.com/.
Organization: Platinum BioLabs
Contact Person: Jesse Witham
Website: https://platinumbiolabs.com/
Email: Send Email
Country: United States
Release id: 50388
View source version on King Newswire:
Retatrutide Clinical Trial Results Highlight Growing Interest in Next-Generation Peptide Research, Says Platinum BioLabs
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.